Dusan Stefoski

发表

Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

Till Sprenger, Gavin Giovannoni, Eva Kubala Havrdova, 2020, Journal of Neurology.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Margaret Burnett, Gavin Giovannoni, 2018, The Lancet.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

Gavin Giovannoni, Xavier Montalban, Ernst-Wilhelm Radue, 2013, The Lancet.

Methylation patterns of cell-free plasma DNA in relapsing–remitting multiple sclerosis

Qilong Yi, A. Reder, V. Levenson, 2010, Journal of the Neurological Sciences.